First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis
出版年份 2020 全文链接
标题
First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis
作者
关键词
-
出版物
Future Oncology
Volume -, Issue -, Pages -
出版商
Future Medicine Ltd
发表日期
2020-10-21
DOI
10.2217/fon-2020-0643
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison
- (2019) Michael B Atkins et al. Immunotherapy
- Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma
- (2019) Sophia Kreft et al. EUROPEAN JOURNAL OF CANCER
- Real-world treatment patterns and clinical outcomes among patients with advanced melanoma
- (2019) C. Lance Cowey et al. MEDICINE
- Real-world experience with pembrolizumab in patients with advanced melanoma
- (2019) Frank Xiaoqing Liu et al. MEDICINE
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era
- (2019) Vito Vanella et al. Current Oncology Reports
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
- (2019) Justin C. Moser et al. Cancer Medicine
- Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
- (2019) Hamid et al. Cancers
- Melanoma and Immune Checkpoint Inhibitors
- (2018) Masutaka Furue et al. Current Oncology Reports
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma
- (2018) Ahmad Tarhini et al. Immunotherapy
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
- (2015) C. Robert et al. EUROPEAN JOURNAL OF CANCER
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
- (2011) C. Garbe et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now